Signals
Life insurers are moving from pricing metabolic risk to trying to reduce it
At the 2026 LIMRA Annual Conference, insurers and health companies argued that obesity, diabetes and insulin resistance should be treated not only as underwriting risks but as modifiable drivers of mortality, disability and claims.
Before a TB Vaccine Exists, Africa Is Building the Route to People
Europe’s next stroke bet: can Factor XIa inhibition change prevention without raising bleeding risk?
MASH, a serious fatty liver disease, is becoming a cardiometabolic condition
Cervical Cancer Cannot Be Left Waiting at the Edge of the ADC Era
Mental Health Patients Need Care, Not Surveillance
ESC Cardio-Oncology 2026: Cancer therapy is getting smarter. Cardiac protection is still playing catch-up.
ENDO 2026 reveals the GLP-1 revolution’s real challenge: delivery
Prostate Cancer Access Moves Into the Veterans System
Mental Health Patients Need Care, Not Surveillance
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.